KR101136260B1 - 감마-세크레타제 억제제로서의 아제핀 유도체 - Google Patents

감마-세크레타제 억제제로서의 아제핀 유도체 Download PDF

Info

Publication number
KR101136260B1
KR101136260B1 KR1020107002906A KR20107002906A KR101136260B1 KR 101136260 B1 KR101136260 B1 KR 101136260B1 KR 1020107002906 A KR1020107002906 A KR 1020107002906A KR 20107002906 A KR20107002906 A KR 20107002906A KR 101136260 B1 KR101136260 B1 KR 101136260B1
Authority
KR
South Korea
Prior art keywords
methyl
phenyl
compound
azin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107002906A
Other languages
English (en)
Korean (ko)
Other versions
KR20100032924A (ko
Inventor
멜린다 조이 호프 밀러
워렌 제이예 포터
존 케빈 렐
알무데나 루비오-에스테반
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20100032924A publication Critical patent/KR20100032924A/ko
Application granted granted Critical
Publication of KR101136260B1 publication Critical patent/KR101136260B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107002906A 2007-08-14 2008-08-04 감마-세크레타제 억제제로서의 아제핀 유도체 Expired - Fee Related KR101136260B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
US60/955,720 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (2)

Publication Number Publication Date
KR20100032924A KR20100032924A (ko) 2010-03-26
KR101136260B1 true KR101136260B1 (ko) 2012-04-19

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107002906A Expired - Fee Related KR101136260B1 (ko) 2007-08-14 2008-08-04 감마-세크레타제 억제제로서의 아제핀 유도체

Country Status (11)

Country Link
US (1) US8188069B2 (enExample)
EP (1) EP2178844A1 (enExample)
JP (1) JP5385904B2 (enExample)
KR (1) KR101136260B1 (enExample)
CN (1) CN101778826B (enExample)
AU (1) AU2008287124B2 (enExample)
BR (1) BRPI0815135A2 (enExample)
CA (1) CA2694209C (enExample)
EA (1) EA017286B1 (enExample)
MX (1) MX2010001754A (enExample)
WO (1) WO2009023453A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
AU2013312305B2 (en) 2012-09-07 2018-06-28 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
EP2897946B1 (en) 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors
WO2014047391A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2016515625A (ja) 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2004031154A1 (en) 2002-10-03 2004-04-15 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2004031154A1 (en) 2002-10-03 2004-04-15 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Also Published As

Publication number Publication date
KR20100032924A (ko) 2010-03-26
CN101778826B (zh) 2012-10-31
JP2010536766A (ja) 2010-12-02
CA2694209A1 (en) 2009-02-19
EA017286B1 (ru) 2012-11-30
CN101778826A (zh) 2010-07-14
BRPI0815135A2 (pt) 2015-02-03
AU2008287124A1 (en) 2009-02-19
MX2010001754A (es) 2010-05-14
US20100197660A1 (en) 2010-08-05
CA2694209C (en) 2013-09-17
EP2178844A1 (en) 2010-04-28
AU2008287124B2 (en) 2013-06-06
EA201070278A1 (ru) 2010-06-30
WO2009023453A1 (en) 2009-02-19
US8188069B2 (en) 2012-05-29
JP5385904B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
KR101136260B1 (ko) 감마-세크레타제 억제제로서의 아제핀 유도체
JP4116437B2 (ja) β−アミロイドペプチドの放出および／または合成を阻害するラクタム化合物
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
JP2010517954A (ja) ６−オキソ−６，７−ジヒドロ−５Ｈ−ジベンゾ［ｂ，ｄ］アゼピン−７−イル誘導体
US7468365B2 (en) Lactam compound
EP1353910B1 (en) Lactam compound
HU210581B (en) Process for prep. of glycinamide deriv.s and pharmaceutical compn.s contg. them
AU2002224321A1 (en) Lactam compound
JP2004521084A5 (enExample)
KR20010033408A (ko) 폴리시클릭 α-아미노-ε-카프롤락탐 및 관련 화합물
CN106661053B (zh) 吡啶基-三氮杂二环类化合物
CA2390376A1 (en) .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
EP1345955B1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
EP0093805A1 (en) Octahydro-2-(omega-mercaptoalkanoyl)3-oxo-1H-isoindole-1-carboxylic acids and esters
US20040077627A1 (en) Lactam compound
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
HK1232868B (zh) 吡啶基-三氮杂二环类化合物
MXPA00005540A (en) POLYCYCLIC&agr;-AMINO-?-CAPROLACTAMS AND RELATED COMPOUNDS

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150406

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150406